🕒 Last update: loading…

Stock Neuronetics, Inc. STIM

Neuronetics, Inc. — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met.

  • ❌ Price trend failed
  • ⚠️ Mixed growth
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2018 → 2019: -76.80%

Price change 2019 → 2020: 147.44%

Price change 2020 → 2021: -59.86%

Price change 2021 → 2022: 54.04%

Price change 2022 → 2023: -57.79%

Price change 2023 → 2024: -44.48%

Price change 2024 → 2025: -14.29%

Price change 2025 → 2026: 60.87%

Price change 2026 (year to date): 54.17%

Financial growth

Revenue CAGR (8 years): 16.00%

Earnings CAGR (8 years): N/A

Growth status: positive trend (>1%/yr) in revenue, earnings data insufficient/N/A.

Debt

Debt-to-equity ratio: 4.04

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -4.91

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 32.73% from the high over 6 months.

Excessive correction (> 20.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Neuronetics, Inc.–4.04+17.8 %🔒
Organogenesis Holdings Inc.27.00.31––
OrganiGram Holdings Inc.2.00.03––
Adocia S.A.–5.97+18.8 %–
Guerbet S.A.–1.64+5.5 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Neuronetics, Inc. over the latest fiscal years.

Revenue
149 m USD
fiscal year 2025
Net income
-39.0 m USD
fiscal year 2025
Net margin
-26.1 %
fiscal year 2025
Average annual growth
+24.8 %
Revenue growth over 5 years
Market cap
108 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
202049.2 m-27.5 m-55.8 %n/a
202155.3 m-31.2 m-56.4 %+12.3 %
202265.2 m-37.2 m-57.0 %+17.9 %
202371.3 m-30.2 m-42.3 %+9.4 %
202474.9 m-43.7 m-58.4 %+5.0 %
2025149 m-39.0 m-26.1 %+99.2 %

Amounts converted to USD. Source: published annual accounts, collected on 13/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Neuronetics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
average accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-3.35
risk zone (below 1.81)
Piotroski Score
4 / 9
4 to 6: average accounts
Net Debt / EBITDA
-5.44 x
net cash
Fiscal year20212022202320242025
Cash and investments96.3 m71.9 m60.6 m19.7 m34.4 m
Total Debt39.5 m39.7 m62.5 m82.6 m90.3 m
Net Debt-54.6 m-30.6 m2.8 m63.2 m56.2 m
Equity85.2 m57.1 m34.2 m27.7 m22.4 m
Total assets141 m117 m116 m141 m142 m
Operating cash flow-28.0 m-30.7 m-32.0 m-31.0 m-20.4 m
Investments (capex)2.4 m3.3 m2.4 m1.5 m801,000
Free cash-flow-30.3 m-34.0 m-34.4 m-32.5 m-21.2 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-4.44 x
Price / book value5.89 x
Return on Equity (ROE)-127.9 %
Return on Invested Capital (ROIC)-13.6 %
Net margin-14.4 %
Debt / equity4.69 x
Current ratio2.01 x
Interest coverage-1.74 x
Free cash-flow yield-7.6 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 18/11/2026.

+

Analyst consensus and forecasts

What the financial analysts covering Neuronetics, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
buy
8 analysts

Breakdown of ratings

strong buy 0buy 7hold 1sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 6 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 14/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Neuronetics, Inc.

Large funds tracked
18
hold the stock as of 2026Q2
Executives (insiders)
4 / 6
4 purchases, 6 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Vanguard Group2.6 m3.6 m0.0 %-8.8 %2025Q4
Citadel Advisors843,8061.1 m0.0 %+1,001.6 %2026Q2
BlackRock596,622775,6080.0 %-74.3 %2026Q2
State Street580,598754,7780.0 %-31.1 %2026Q2
Marshall Wace485,692631,4000.0 %n/a2026Q2
Geode Capital Management458,474596,2420.0 %-52.2 %2026Q2
Goldman Sachs264,088343,3140.0 %+13.1 %2026Q2
Millennium Management199,450259,2850.0 %n/a2026Q2

Latest insider transactions

DatePersonSideAmount
13/11/2026Chernett Joreysale2.5 m USD
12/11/2026Chernett Joreysale1.0 m USD
11/11/2026Chernett Joreysale139,679 USD
09/11/2026Chernett Joreysale214,156 USD
09/11/2026Chernett Joreypurchase79,600 USD
06/11/2026Chernett Joreysale599,422 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 18/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 28/06/2018
ISIN code
US64131A1051
Workforce
716
full-time employees
Chief executive
Keith J. Sullivan

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Neuronetics, Inc.

What is the Neuronetics, Inc. share price?

Latest recorded price: 1.39 USD on 13/11/2026, for a market cap of 108 m USD.

What is the revenue of Neuronetics, Inc.?

149 m USD for fiscal year 2025, with net income of -39.0 m USD (net margin -26.1 %).

What do analysts say about Neuronetics, Inc.?

Out of 8 analysts: 7 buy or strong buy, 1 hold, 0 sell or strong sell.

Is Neuronetics, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US64131A1051).

How many employees does Neuronetics, Inc. have?

716 full-time employees according to the latest published profile.

Who runs Neuronetics, Inc.?

Keith J. Sullivan is the company's chief executive.

Which large funds own Neuronetics, Inc.?

As of 2026Q2, among the large funds tracked: Vanguard Group, Citadel Advisors, BlackRock, State Street, Marshall Wace.

07

Similar stocks